Characterization of the role of nitric oxide and its clinical applications

Cardiology (Switzerland)

Volumn 122, Issue 1, 2012, Pages 55-68

  Levine, Arlene Bradley ^a   Punihaole, David ^a   Levine, T Barry ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Insulin resistance; Metabolism; Mitochondria; Nitric oxide; Skeletal cardiac myocyte

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ARGINASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIUM DERIVED RELAXING FACTOR; FATTY ACID; GLUCOCORTICOID; GLUCOSE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; ORGANIC NITRATE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; REACTIVE OXYGEN METABOLITE; RHO KINASE; TUMOR NECROSIS FACTOR ALPHA; VASODILATOR AGENT;

ANGINA PECTORIS; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; BIOAVAILABILITY; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CALCIUM CELL LEVEL; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL AGING; CELL DEATH; CELL GROWTH; CELL PROTECTION; DIABETES MELLITUS; DIET THERAPY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENERGY RESOURCE; ENZYME ACTIVATION; ERECTILE DYSFUNCTION; EXERCISE; FATTY ACID METABOLISM; GENETIC POLYMORPHISM; GLUCOSE HOMEOSTASIS; HALF LIFE TIME; HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; HEART MUSCLE METABOLISM; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; IMMOBILIZATION; INFLAMMATION; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; ISCHEMIC HEART DISEASE; LONG TERM CARE; MITOCHONDRION; MULTIPLE ORGAN FAILURE; MUSCLE CELL; MUSCLE METABOLISM; NEUROTRANSMISSION; NITROSYLATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; SENESCENCE; SEPSIS; SEPTIC SHOCK; SHEAR STRESS; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STROKE; THROMBOCYTE ACTIVATION; THROMBOSIS; TIME; UNSPECIFIED SIDE EFFECT; VASCULARIZATION; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CELL DEATH; CELL SURVIVAL; CYTOKINES; DIET; ENDOTHELIUM, VASCULAR; EXERCISE; HALF-LIFE; HUMANS; INSULIN RESISTANCE; MICE; MITOCHONDRIA, HEART; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; SHEAR STRENGTH; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATION; VASODILATOR AGENTS;

EID: 84862505871     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000338150     Document Type: Article

References (53)

1. Spier SA, Delp MD, Stallone JN, Dominguez JM 2nd, Muller-Delp JM: Exercise training enhances flow-induced vasodilation in skeletal muscle resistance arteries of aged rats: role of PGI2 and nitric oxide. Am J Physiol Heart Circ Physiol 2007; 292:H3119-H3127. (Pubitemid 47084567)
2. Clementi E, Nisoli E: Nitric oxide and mitochondrial biogenesis: a key to long-term regulation of cellular metabolism. Comp Biochem Physiol A Mol Integr Physiol 2005; 142: 102-e110.
3. Marsh N, Marsh A: A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin Exp Pharmacol Physiol 2000; 27: 313-319. (Pubitemid 30194171)
4. The Nobel Prize in Physiology or Medicine. Nobelprize.org. 2012. http://www.nobelprize. org/nobel/prizes/medicine/.
5. Ignarro LJ: Preface to this special journal issue on nitric oxide chemistry and biology. Arch Pharm Res 2009; 32: 1099-1101.
6. Kone BC, Kuncewicz T, Zhang W, Yu ZY: Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am J Physiol Renal Physiol 2003; 285:F178-F190. (Pubitemid 36871190)
7. Lundberg JO: Nitric oxide metabolites and cardiovascular disease. Markers, mediators, or both? J Am Coll Cardiol 2006; 47: 580-581. (Pubitemid 43170847)
8. Miller MR, Megson IL: Recent developments in nitric oxide donor drugs. Br J Pharmacol 2007; 151: 305-321. (Pubitemid 46842668)
9. Munzel T, Feil R, Mulsch A, Lohmann SM, Hofmann F, Walter U: Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphatedependent protein kinase. Circulation 2003; 108: 2172-2183. (Pubitemid 37363031)
10. Lima B, Forrester MT, Hess DT, Stamler JS: S-Nitrosylation in cardiovascular signaling. Circ Res 2010; 106: 633-646.
11. Parihar MS, Nazarewicz RR, Kincaid E, Bringold U, Ghafourifar P: Association of mitochondrial nitric oxide synthase activity with respiratory chain complex I. Biochem Biophys Res Commun 2008; 1;366: 23-28. (Pubitemid 50008460)
12. Gutierrez J, Ballinger SW, Darley-Usmar VM, Landar A: Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ Res 2006; 99: 924-932. (Pubitemid 44657795)
13. Nisoli E, Carruba MO: Nitric oxide and mitochondrial biogenesis. J Cell Sci 2006; 119: 2855-2862. (Pubitemid 44177863)
14. Dedkova EN, Blatter LA: Modulation of mitochondrial Ca2+ by nitric oxide in cultured bovine vascular endothelial cells. Am J Physiol Cell Physiol 2005; 289:C836-C845. (Pubitemid 41361639)
15. Erusalimsky JD, Moncada S: Nitric oxide and mitochondrial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27: 2524-2531. (Pubitemid 350158901)
16. Duchen MR: Roles of mitochondria in health and disease. Diabetes 2004; 53(suppl 1):S96-S102. (Pubitemid 38168700)
17. Guarente L: Mitochondria-a nexus for aging, calorie restriction, and sirtuins? Cell 2008; 132: 171-176. (Pubitemid 351172441)
18. Gutierrez J, Ballinger SW, Darley-Usmar VM, Landar A: Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ Res 2006; 99: 924-932. (Pubitemid 44657795)
19. Zenebe WJ, Nazarewicz RR, Parihar MS, Ghafourifar P: Hypoxia/ reoxygenation of isolated rat heart mitochondria causes cytochrome c release and oxidative stress; evidence for involvement of mitochondrial nitric oxide synthase. J Mol Cell Cardiol 2007; 43: 411-419. (Pubitemid 47451417)
20. Mitsuishi M, Miyashita K, Itoh H: cGMP rescues mitochondrial dysfunction induced by glucose and insulin in myocytes. Biochem Biophys Res Commun 2008; 21; 367: 840-845.
21. Rakhit RD, Mojet MH, Marber MS, Duchen MR: Mitochondria as targets for nitric oxide-induced protection during simulated ischemia and reoxygenation in isolated neonatal cardiomyocytes. Circulation 2001; 103: 2617-2623. (Pubitemid 32521974)
22. Crouser ED: Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion 2004; 4: 729-741. (Pubitemid 39646818)
23. Kingwell BA: Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease. FASEB J 2000; 14: 1685-1696.
24. Begum N, Sandu OA, Ito M, Lohmann SM, Smolenski A: Active Rho kinase (ROK-alpha) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. J Biol Chem 2002; 277: 6214-6222. (Pubitemid 34968412)
25. Higaki Y, Hirshman MF, Fujii N, Goodyear LJ: Nitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle. Diabetes 2001; 50: 241-247. (Pubitemid 32127278)
26. Jobgen WS, Fried SK, Fu WJ, Meininger CJ, Wu G: Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem 2006; 17: 571-588. (Pubitemid 44205442)
27. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387-389.
28. Hayden MR, Tyagi SC: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol 2003; 2: 2.
29. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S: Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003; 9: 1370-1376. (Pubitemid 37466185)
30. Levonen AL, Patel RP, Brookes P, Go YM, Jo H, Parthasarathy S, Anderson PG, Darley-Usmar VM: Mechanisms of cell signaling by nitric oxide and peroxynitrite: from mitochondria to MAP kinases. Antioxid Redox Signal 2001; 3: 215-229. (Pubitemid 32473338)
31. Förstermann U: Nitric oxide and oxidative stress in vascular disease. Pflügers Arch 2010; 459: 923-939.
32. Kim F, Pham M, Maloney E, Rizzo NO, Morton GJ, Wisse BE, Kirk EA, Chait A, Schwartz MW: Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol 2008; 28: 1982-1988.
33. Cooke JP: Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-2037.
34. Colombo MG, Andreassi MG, Paradossi U, Botto N, Manfredi S, Masetti S, Rossi G, Clerico A, Biagini A: Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298[ Asp polymorphism) to the presence, extent, and severity of coronary artery disease. Heart 2002,87: 525-528. (Pubitemid 34547974)
35. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, Caldwell RB, Caldwell RW: Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008; 102: 95-102.
36. Kim F, Gallis B, Corson MA: TNF-alpha inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. Am J Physiol Cell Physiol 2001; 280:C1057-C1065.
37. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454. (Pubitemid 40396812)
38. Hsueh WA, Quinones MJ: Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003; 92(suppl):10J-17J.
39. Kingwell BA: Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease. FASEB J 2000; 14: 1685-1696.
40. Davies PF, Civelek M, Fang Y, Guerraty MA, Passerini AG: Endothelial heterogeneity associated with regional athero-susceptibility and adaptation to disturbed blood flow in vivo. Semin Thromb Hemost 2010; 36: 265-275.
41. Suvorava T, Lauer N, Kojda G: Physical inactivity causes endothelial dysfunction in healthy young mice. J Am Coll Cardiol 2004; 44: 1320-1327. (Pubitemid 39208892)
42. Libby P: Inflammation in atherosclerosis. Nature 2002; 420: 868-874. (Pubitemid 36019640)
43. Widlansky ME, Gokce N, Keaney JJ, Vita JA: The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-1160. (Pubitemid 37188333)
44. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazzini T, Nicod P, Thorens B, Scherrer U: Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001; 104: 342-345. (Pubitemid 32666958)
45. Rizzo NO, Maloney E, Pham M, Luttrell I, Wessells H, Tateya S, Daum G, Handa P, Schwartz MW, Kim F: Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by highfat feeding. Arterioscler Thromb Vasc Biol 2010; 30: 758-765.
46. Zhang Y, Janssens SP, Wingler K, Schmidt HH, Moens AL: Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. Am J Physiol Heart Circ Physiol 2011; 301:H634-H646.
47. Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, Falcone S, Valerio A, Cantoni O, Clementi E, Moncada S, Carruba MO: Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 2005; 310: 314-317. (Pubitemid 41457197)
48. Jankowski P, Safar ME, Benetos A: Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system. Curr Pharm Des 2009; 15: 571-584.
49. Javed U, Deedwania PC: Angiotensin receptor blockers: novel role in high-risk patients. Cardiol Clin 2008; 26: 507-526.
50. Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L: Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs 2010; 70: 41-56.
51. Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA: Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol 2012; 59: 9-15.
52. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118. (Pubitemid 40261799)
53. Heemskerk S, Masereeuw R, Russel FG, Pickkers P: Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury. Nat Rev Nephrol 2009; 5: 629-640.